EA201101638A1 - Новые твердые формы {[(2s,5r,8s,11s)-5-бензил-11-(3-гуанидинопропил)-8-изопропил-7-метил-3,6,9,12,15-пентаоксо-1,4,7,10,13-пентаазациклопентадец-2-ил]уксусной кислоты} и способы их получения - Google Patents

Новые твердые формы {[(2s,5r,8s,11s)-5-бензил-11-(3-гуанидинопропил)-8-изопропил-7-метил-3,6,9,12,15-пентаоксо-1,4,7,10,13-пентаазациклопентадец-2-ил]уксусной кислоты} и способы их получения

Info

Publication number
EA201101638A1
EA201101638A1 EA201101638A EA201101638A EA201101638A1 EA 201101638 A1 EA201101638 A1 EA 201101638A1 EA 201101638 A EA201101638 A EA 201101638A EA 201101638 A EA201101638 A EA 201101638A EA 201101638 A1 EA201101638 A1 EA 201101638A1
Authority
EA
Eurasian Patent Office
Prior art keywords
solid forms
benzyl
methods
acetic acid
pentaox
Prior art date
Application number
EA201101638A
Other languages
English (en)
Other versions
EA022831B1 (ru
Inventor
Альфред Йончик
Клеменс Кюн
Керстин Земанн
Кристоф Заль
Геральд Шольц
Зёнке Петерзен
Харальд Унтенеккер
Михаэль Ланге
Original Assignee
Мерк Патент Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Патент Гмбх filed Critical Мерк Патент Гмбх
Publication of EA201101638A1 publication Critical patent/EA201101638A1/ru
Publication of EA022831B1 publication Critical patent/EA022831B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Настоящее изобретение относится к новым твердым формам {[(2S,5R,8S,11S)-5-бензил-11-(3-гуанидинопропил)-8-изопропил-7-метил-3,6,9,12,15-пентаоксо-1,4,7,10,13-пентаазацикпопентадец-2-ил]уксусной кислоты}, способам их получения и применению упомянутых твердых форм в фармацевтических препаратах.
EA201101638A 2009-05-20 2010-05-20 Твердые формы {[(2s,5r,8s,11s)-5-бензил-11-(3-гуанидинопропил)-8-изопропил-7-метил-3,6,9,12,15-пентаоксо-1,4,7,10,13-пентаазациклопентадец-2-ил]уксусной кислоты} и способы их получения EA022831B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09006790 2009-05-20
PCT/EP2010/003100 WO2010133367A2 (en) 2009-05-20 2010-05-20 Novel solid materials of {[2s, 5r,8s,11s)-5-benzyl-11-(3-guanidino-propyl)-8-isopropyl-7-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid} and methods for obtaining them

Publications (2)

Publication Number Publication Date
EA201101638A1 true EA201101638A1 (ru) 2012-06-29
EA022831B1 EA022831B1 (ru) 2016-03-31

Family

ID=41338466

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201101638A EA022831B1 (ru) 2009-05-20 2010-05-20 Твердые формы {[(2s,5r,8s,11s)-5-бензил-11-(3-гуанидинопропил)-8-изопропил-7-метил-3,6,9,12,15-пентаоксо-1,4,7,10,13-пентаазациклопентадец-2-ил]уксусной кислоты} и способы их получения

Country Status (14)

Country Link
US (2) US8586545B2 (ru)
EP (2) EP3085704A1 (ru)
JP (1) JP5878864B2 (ru)
KR (1) KR20120060947A (ru)
CN (1) CN102428098B (ru)
AU (1) AU2010251385B2 (ru)
BR (1) BRPI1012789A2 (ru)
CA (1) CA2762652C (ru)
EA (1) EA022831B1 (ru)
ES (1) ES2578026T3 (ru)
HK (1) HK1169832A1 (ru)
MX (1) MX2011012231A (ru)
WO (1) WO2010133367A2 (ru)
ZA (1) ZA201109327B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2346524A2 (en) * 2008-11-20 2011-07-27 Merck Patent GmbH New therapy and medicament using integrin ligands for treating cancer
CN102652015B (zh) * 2009-12-10 2016-08-03 默克专利有限公司 包含寡肽、优选西仑吉肽的药物组合物
ES2720477T3 (es) * 2011-06-09 2019-07-22 Merck Patent Gmbh Tratamiento de cánceres y metástasis con suspensiones de Cilengitide en portador

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19534177A1 (de) * 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
WO1998057648A1 (en) 1997-06-16 1998-12-23 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound
UA71608C2 (en) * 1999-03-11 2004-12-15 Merck Patent Gmbh A method for producing the cyclic pentapeptide
CN102652015B (zh) * 2009-12-10 2016-08-03 默克专利有限公司 包含寡肽、优选西仑吉肽的药物组合物

Also Published As

Publication number Publication date
CN102428098B (zh) 2014-11-05
HK1169832A1 (en) 2013-02-08
EP2432801B1 (en) 2016-03-23
EP2432801A2 (en) 2012-03-28
WO2010133367A2 (en) 2010-11-25
AU2010251385A8 (en) 2012-02-16
BRPI1012789A2 (pt) 2018-01-16
JP5878864B2 (ja) 2016-03-08
AU2010251385B2 (en) 2016-04-14
AU2010251385A1 (en) 2012-01-19
WO2010133367A3 (en) 2011-10-27
ES2578026T3 (es) 2016-07-20
CA2762652A1 (en) 2010-11-25
EA022831B1 (ru) 2016-03-31
ZA201109327B (en) 2012-08-29
US20140088022A1 (en) 2014-03-27
JP2012527417A (ja) 2012-11-08
US20120065142A1 (en) 2012-03-15
US8765684B2 (en) 2014-07-01
EP3085704A1 (en) 2016-10-26
US8586545B2 (en) 2013-11-19
CN102428098A (zh) 2012-04-25
KR20120060947A (ko) 2012-06-12
MX2011012231A (es) 2011-12-08
CA2762652C (en) 2018-10-02

Similar Documents

Publication Publication Date Title
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
CA2796215C (en) Compositions and methods for brain delivery of analgesic peptides
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
EA201270722A1 (ru) Формы рифаксимина и их применение
EA201500650A1 (ru) Фенилацетат l-орнитина и способы его получения
CR20110470A (es) Proteínas de union a il-17
EA201390993A1 (ru) Антитела к cd38
WO2012064792A3 (en) Protein complexes for antigen binding and methods of use
BR112013013167A8 (pt) inibidores de bromodomínio e usos dos mesmos
ECSP13012668A (es) Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso
EA201170962A1 (ru) Препарат разагилина с отсроченным высвобождением действующего вещества
EA201370018A1 (ru) Составы рифаксимина и их применение
WO2011086093A3 (en) Pharmaceutical compositions for oral administration of insulin peptides
EA201290032A1 (ru) Синтез и применение вилдаглиптина для получения лекарственных форм
BR112014008700A2 (pt) composições úteis no tratamento de nefropatia e processos para preparação das mesmas
EP3808378A8 (en) Therapeutic proteins with increased half-life and methods of preparing same
EA201291050A1 (ru) Комбинация лекарств с протеинсвязывающими пролекарствами
MX365205B (es) Preparaciones liofilizadas de melfalán flufenamida.
EA201490653A1 (ru) Производные эстра-1,3,5(10),16-тетраен-3-карбоксамида, способ их получения, содержащие их фармацевтические препараты, а также их применение для получения лекарственных средств
WO2012006014A3 (en) Multi-component pharmaceuticals for treating diabetes
WO2012087160A3 (en) Anti-inflammatory proteins and methods of preparation and use thereof
EA201490901A1 (ru) Линкеры на основе тирозина для свободного соединения пептидов
BR112012010760A2 (pt) caldo de fermentação inseticida a partir de actinomicetos
EA201200095A1 (ru) Фармацевтические композиции и твердые формы

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): MD TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU